Report of Two COVID-19 ARDS (CARDS) Cases Who Survived without Intubation and Mechanical Ventilation
The most severe clinical feature of COVID-19 is Acute Respiratory Distress Syndrome (ARDS) which requires intubation and mechanical ventilation and it occurs in approximately 2.3% of cases. About 94% of of these cases end in death. This case series report two confirmed COVID-19 patients who had met criteria of intubation and mechanical ventilation, but not performed to them. Both patients experienced clinical improvement and recovery. Probably this is due to differences of COVID-19 ARDS (CARDS) with typical or classic ARDS. CARDS is divided into two phenotypes of type L (Low Elastance) and type H (High Elastance). These different phenotypic also distinguish subsequent pathophysiology and clinical management. These phenotype can be differentiate by chest CT scan. This case series emphasizes the importance of understanding this phenotype so that clinicians can provide more appropriate treatment management and also availability of CT scans in health facilities that manage COVID -19.
WHO. Clinical management of severe acute respiratory infection when COVID-19 is suspected. Interim Guidance 13 Maret 2020.
WHO. Coronavirus disease 2019 (COVID019) situation report - 59. Accessed March 20, 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200319-sitrep-59-covid-19.pdf.
Yao W, Wang T, Jiang B, et al. Emergency tracheal intubation in 202 patients with COVID-19 in Wuhan, China: lessons learnt and international recommendations. Brit J Anaesthesia Elsevier. 2020; 11(2):3-4.
Riviello ED, Buregeya E, Twagirumugabe T. Diagnosing acute respiratory distress syndrome in resource limited settings: the Kigali modification of the Berlin definition. Curr Opin Crit Care. 2017;23:18-23.
Meng L, Qiu H, Wan L, et al. Intubation and ventilation amid the COVID-19 outbreak. Anesthesiol. 2020; 16(6):3-8.
Vincent J, Taccone F, et al. Understanding pathways to death in patients with COVID-19. Lancet Respir Med. 2020;3.
Gattinoni L, Chiumello D, Caironi P, et al. COVID-19 pneumonia: different respiratory treatment for different phenotypes? Intensive Care Medicine. 2020;3.
Woods A. COVID-19 not your “typical” ARDS. Lippincott 2020 DIkutip dari https://wwwnursingcentercom/ncblog/april-2020/covid-19-not-your-typical-ards.
Siddiqi H, Mehra M, et al. COVID-19 illness in native and immunosuppressed state. J Heart Lung Transplant. 2020.
Cao X. COVID-19: Immunopathology and its implications for theraphy. Nature Rev Immunol. 2020; 20.
Henderson, Canna S, Schulert G, et al. On the alert for cytokine storm: Immunopathology in COVID-19. Research Gate 2020.
Ye Q, Wang B, Mao J, et al. Cytokine storm in COVID-19 and treatment. Elsevier 2020.
Wenjun W, Xiaoqing L, Sipei W, et al. The definition and risk of cytokine release syndrome-like in 11 COVID-19 infected pneumonia critically ill patients: disease characteristics and retrospective analysis. MedRxiv 2020.
Diamanti A, Rosado M, Pioli C, et al. Cytokine release syndrome in COVID-19 patients, a new scenario for an old concern: the fragile balance between infections and autoimmunity. Int J Mol Sci. 2020;21.
Liu J, Li S, Liu JJ, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. Elsevier. 2020;55.
Yuan J, Zou R, Zeng L, et al. The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients. Inflammation Res. 2020;69.
Marini J, Gattinoni L. Management of COVID-19 respiratory distress. JAMA. 2020 Published online April 24, 2020 doi:101001/jama20206825.
Zhao M. Cytokine storm and immunomudulatory theraphy in COVID-19: role of chloroquine and anti-IL-6 monoclonal antibodies. Elsevier. 2020;20.
- There are currently no refbacks.